Viridian Therapeutics Inc.

10/21/2025 | Press release | Distributed by Public on 10/21/2025 14:35

Business/Financial Results (Form 8-K)

Item 2.02

Results of Operations and Financial Condition.

On October 21, 2025, the Company announced that while it has not finalized its full financial results for the quarter ended September 30, 2025, the Company expects to report that it had approximately $490.9 million of cash, cash equivalents and marketable securities as of September 30, 2025.

This amount is preliminary, has not been audited and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to this preliminary information and, accordingly, does not express an opinion or any other form of assurance with respect thereto. Consequently, this amount may differ materially from the amount that will be reflected in the Company's unaudited condensed consolidated balance sheet as of September 30, 2025.

The information in this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly provided by specific reference in such filing.

Viridian Therapeutics Inc. published this content on October 21, 2025, and is solely responsible for the information contained herein. Distributed via EDGAR on October 21, 2025 at 20:35 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]